This link will take you to the electronic medicines compendium (emc) website, which is a non-Novartis website.
KESIMPTA®▼ (ofatumumab) real-world experience
KESIMPTA is indicated for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS) with active disease defined by clinical or imaging features.1
Please refer to the Summary of Product Characteristics for full safety information, and the safety profile page here.
Watch this short video to learn about real-world experience with KESIMPTA.
VIDEO
KESIMPTA is an established subcutaneous B-cell therapy with up to 7 years of clinical trial experience and 4 years of real-world experience in >140,000 patients with RMS globally.*1–3
*144,918 patients received treatment as of December 2024.3
RMS, relapsing multiple sclerosis.
References
KESIMPTA (ofatumumab) Summary of Product Characteristics.
Pardo G, et al. Poster P7016. American Academy of Neurology Annual Meeting. 5–8 April 2025, San Diego, CA, US.
Novartis Data on File. OFA 034.
UK | October 2025 | FA-11499014
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis online through the pharmacovigilance intake (PVI) tool at www.novartis.com/report, or alternatively email [email protected] or call 01276 698370.
Welcome to Pro.Novartis.com
The Novartis portal for UK healthcare professionals (HCPs) and other relevant decision makers* is where you can find promotional information about Novartis products, therapy area materials and professional resources.
*Other relevant decision makers particularly includes those with an NHS role who could influence in any way the administration, consumption, prescription, purchase, recommendation, sale, supply or use of any medicine but who are not health professionals.
This website is designed to be viewed on desktop.
Welcome to Pro.Novartis.com
The Novartis portal for UK healthcare professionals (HCPs) and other relevant decision makers* is where you can find promotional information about Novartis products, therapy area materials and professional resources.
*Other relevant decision makers particularly includes those with an NHS role who could influence in any way the administration, consumption, prescription, purchase, recommendation, sale, supply or use of any medicine but who are not health professionals.
This website is designed to be viewed on desktop.